Testing effectiveness (Phase 2)UnknownNCT01255527
What this trial is testing
Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study
Who this might be right for
Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation
Yonsei University 53